In Germany, health insurance companies will soon have to pay for corona vaccines. A look at the USA shows that the negotiations could be tough. source site
medicine Moderna Wants Approval for RSV Vaccine for Elderly Moderna wants to fight the RS virus with a vaccination. photo © Nicolas Armer/dpa RSV has recently placed a particularly heavy burden on children's hospitals. Moderna is now announcing data on a vaccine against the virus – but initially this is only intended for people over 60 years of age. The US company Moderna wants to apply for approval for an RSV vaccine for adults over 60 years of age in...
Status: 01/18/2023 12:44 p.m The RSV wave has put a lot of strain on the children's hospitals. The US company Moderna now wants to apply for approval for an mRNA vaccine against the virus. But this is only intended for older people - for the time being. By Angela Göpfert, tagesschau.de RSV: So far, many have only associated this with babies and small children. The respiratory syncytial virus had ensured full children's hospitals, especially in November and December. Intensive care...
The vaccine developed is initially intended for people aged 60 and over. However, RSV can also be particularly dangerous for infants and young children. Moderna is also doing research on this, said Burton. "We have five other ongoing programs for young children, pregnant mothers and a number of other populations. We will be releasing this data in the coming months." RSV had placed a heavy burden on children's hospitals in Germany and other countries this season. The combination of many...
medicine Moderna to seek approval for RSV vaccine for elderly Moderna wants to use a vaccination to fight the RSV virus, which is particularly dangerous for babies and young children. photo © Nicolas Armer/dpa RSV has recently placed a particularly heavy burden on children's hospitals. Moderna is now announcing data on a vaccine against the virus – but initially this is only intended for people over 60 years of age. The US company Moderna wants to apply for approval for...
Moderna, which developed one of the first messenger RNA vaccines against Covid-19, unveiled positive preliminary results on Tuesday for a trial of respiratory syncytial virus (RSV), which causes bronchiolitis, in the elderly.This phase 3 trial is being conducted double-blind on 37,000 people aged 60 and over in 22 countries, including the United States. According to interim data, the potential messenger RNA vaccine showed nearly 84% efficacy and was well tolerated. Of 64 cases of patients with the virus, presenting two...
Biontech and its partner Pfizer took a while to respond to US competitor Moderna's patent lawsuit. On Monday, Pfizer and Biontech launched a counterattack against Moderna. They sued the US company in federal court in Boston. According to media reports, they are requesting that Moderna's lawsuit be dismissed and that its patents have not been infringed upon.This counterclaim is directed against a lawsuit that Moderna filed in both the United States and Germany at the end of August. Moderna alleges...
Status: 06.12.2022 10:13 a.m Moderna as well as BioNTech and Pfizer use the novel mRNA technology for the corona vaccines. After Moderna sued the two companies for patent infringement, they are now filing a counterclaim. The US pharmaceutical company Pfizer and its German partner BioNTech have filed a lawsuit in a Boston federal court against the US biotech group Moderna in a dispute over competing corona vaccines. It sought the dismissal of Moderna's lawsuit and a declaration that Moderna's patents...
The US biotech group Moderna has to cut sales targets for its Covid 19 vaccine this year due to supply bottlenecks. For 2022, sales of Covid-19 vaccines are now expected to be between $18 billion and $19 billion instead of $21 billion, the company announced on Thursday. Details of the delivery problems were not given. Moderna's coronavirus vaccine sales fell 35 percent to $3.1 billion in the third quarter. The group's net profit shrank to a good billion dollars from...
American laboratories Moderna and Merck announced on Wednesday that they have entered into an agreement to jointly develop and market a messenger RNA vaccine currently being tested in combination with an anti-cancer drug for patients at high risk of skin cancer. Moderna and Merck, whose products are marketed under the MSD name outside North America, have been collaborating since 2016 on the development of a cancer vaccine.Under the terms of their agreement, Merck will now pay Moderna $250 million to...
